Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

Syntex LLC

F. Hoffmann-la Roche Ag

Saul Jaime-Figueroa

Robert J Greenhouse

Ralph New Harris, Iii

David Bruce Repke

Russell Stephen Stabler

James M Kress

Lee Allen Flippin

Shu-Hai Zhao

Jacob Berger

Aubry Kern Miller

Lubica Raptova

Klaus Kurt Weinhardt

David George Putman

Yanzhou Liu

Robert James Weikert

Karin Ann Stein

David John Morgans, Jr

Eric Brian Sjogren

Jurg R Pfister

Francisco Javier Lopez-Tapia

Todd Richard Elworthy

Stephen Matthew Lynch

Angel Guzman

Francisco X Talamas

Deborah Carol Reuter

Gary W Bantle

Arturo Perez-Medrano

Robert Greenhouse

Ralph New Harris Iii

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Tetralin and indane derivatives and uses thereof

Compounds of formula I: or pharmaceutically acceptable salts, solvates or prodrugs thereof,

3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors

The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R, R, R, R, R, R, Rand Rare defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

3-Amino-1-arylpropyl azaindoles and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof,

This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I:wherein X is &#x2014;S(O)&#x2014; or &#x2014;C(O)&#x2014;, A is Calkyl, aryl, heteroaryl, hydroxyalkyl, or &#x2014;(CH)&#x2014;NRR, and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Substituted indoles as alpha-1 agonists

The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT.sub.2B -antagonists. The 5-HT.sub.2B antagonist is a compound of the formula: ##STR1## wherein: R.sup.1 is hydrogen, alkyl, lower alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, --NR.sup.6 R.sup.7, --CO.sub.2 R.sup.8, --O(CH.sub.2).sub.n R.sup.9, or lower alkyl optionally substituted with hydroxy, alkoxy, halo, or aryl; in which

Aryl pyrimidine derivatives and uses thereof

The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT.sub.2B -antagonists.

Aryl pyrimidine derivatives

The disclosed pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, in particular use as selective 5HT.sub.2B -antagonists. The invention is also directed to formulations and methods for treatment.

Compounds of Formula I: ##STR1## where R.sup.5 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## and the pharmaceutically acceptable salts and N-oxides thereof, are .alpha..sub.1 -adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

Pyrimidinedione, pyrimidinetrione, triazinedione and

Growing community of inventors

Fremont, CA, United States of America

Saul Jaime-Figueroa